BioCentury on BioBusiness,
How Celgene builds stable of venture plays without corporate VC arm
Related tables, figures and sidebars
Celgene's venture model
Monday, November 19, 2012
Although it has eschewed creating a corporate venture arm, Celgene
Corp. has been an active investor in private biotechs for at least the
last five years, tapping a network of scientists and VCs to identify companies
and academics working in the big biotech's areas of interest. But last month's
investment in cancer and fibrotic disease company PharmAria
LLC was the first time Celgene has seeded a company.
The funds will allow PharmAria
to begin identifying clinical candidates against undisclosed targets. Celgene
received an option to license undisclosed R&D programs and an option,
triggered by an undisclosed event, to acquire the company.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]